ET Now on MSN
Top private universities in Delhi NCR 2026
This article shares details about the top private universities in Delhi NCR for 2026. It covers universities like Bennett ...
Vir Biotechnology, Inc. today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) ...
Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues -- Astellas to lead ...
Regtechtimes on MSN
Healthcare administrator Ayesha Islam Asha drives operational excellence in New York's home care sector
NEW YORK – As regulatory complexity intensifies and demand for home healthcare continues to rise, Ayesha Islam Asha has emerged as a results-driven administrative leader focused on operational ...
Charlotte officially announced the hire of its new athletic director on Monday morning, with Kevin White joining the 49ers ...
Ownwell raises $50M to scale property tax monitoring and appeals, helping homeowners save on taxes and reduce homeownership ...
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, ...
Q1 beat drives 39% order growth, record $18.2B backlog, and raised EPS outlook; DCF says Buy with $158 target. Click here to ...
As part of its broader global growth strategy, Steelforce Packaging has organized its North American operations under the newly established Steelforce America entity. This structure reflects the ...
Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...
Here is a sneak peek to this week’s headlines. Happy Monday dvm360 readers! For those in the areas of the US hit with the massive snowstorm, we hope you, your families, coworkers, and patients are all ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results